Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Frost & Sullivan Lauds Humacyte for its Game-changing Immunocompatible Vascular Grafts - Humacyte's grafts resolve technical, immunogenic, quantitative and time-related challenges of biomaterials - Awards.Frost.com
Frost & Sullivan Lauds Humacyte for its Game-changing Immunocompatible Vascular Grafts

 

PRZOOM - /newswire/ - Mountain View, CA, United States, 2011/09/30 - Humacyte's grafts resolve technical, immunogenic, quantitative and time-related challenges of biomaterials - Awards.Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent analysis of the vascular grafts market, Frost & Sullivan recognizes Humacyte, Inc. with the 2011 North American Frost & Sullivan Award for New Product Innovation for its vascular grafts. These grafts, produced using the company's tissue engineering extracellular matrix (ECM) technology, satisfies the industrial requirements for an immunocompatible, structurally viable, readily available, and user-friendly synthetic vascular graft.

According to the National Kidney Foundation, approximately 300,000 patients are on dialysis in the United States and around 100,000 new patients are reported each year. More than half of these patients require synthetic vascular grafts to receive bloodstream access for the dialysis process. These numbers become all the more significant considering that polymeric grafts fail at some point in most patients, resulting in complications.

As polymeric grafts are developed using the patient's own cells, they can be used only by that particular patient and its production involves a long wait. Further, these grafts have large diameters and are not suitable for all surgical applications. On the other hand, Humacyte propagates acellular human engineered vascular grafts so they are available off-the-shelf and can be maintained at hospitals to be used on demand and in emergencies.

"Vascular grafts are made of decellularized engineered human tissues, which increase patient acceptance considerably when compared to polymeric vascular grafts," said Frost & Sullivan Research Analyst Tejaswini Prabhu. "Since these grafts can be stored for up to a year and the company is capable of manufacturing multiple products simultaneously, they are instantly available to many patients."

Several companies involved in tissue engineering use the ECM technology, however, the finesse and complexities of vascular grafts renders this technology complex. Humacyte make use of a customized version of ECM wherein human vascular cells from numerous donors are isolated, grown and cultured on a biodegradable tubular scaffold to produce a three dimensional vascular graft. Once grown the tissue grafts are decellularized resulting in an acellular vascular graft that is sturdy, readily available and has a low rate of infection.

Although Humacyte's vascular tissues have higher initial costs than conventional polymer grafts, they help save on repeated surgeries, as they have an impressive in-life span.

"The success of these grafts is attributed to both patient acceptance and the resistance of the grafts to clotting, infection and obstruction," said Tejaswini "They can be engineered to possess small diameters, which allow them to be used in high-end and futuristic applications such as artificial organs and combinational devices."

Each year, Frost & Sullivan presents this award to the company that demonstrates innovation in the development of a product. The recipient leverages leading edge technologies to offer value-added features while increasing the ROI for customers. In turn, the innovation enables the company to acquire new customers and increase their market penetration.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About Humacyte, Inc.
Humacyte, Inc. was founded in 2004 in North Carolina, USA by Dr. Laura Nikalson, Dr, Juliana Blum and Dr, Shannon Dahl to commercially manufacture off-the-shelf synthetic vascular grafts using the patented cell-based process. Since its inception, the company has been growing medical devices from human cells. Apart from its vascular graft products, Humacyte Inc. manufactures therapeutic filler products for tissue repair and regeneration. Presently, the company is working on upscaling their manufacturing process and increasing the storage time of its vascular grafts. In addition, the company is actively involved in several R&D pipeline products taking advantage of the depth of their ECM platform technology .

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Lauds Humacyte for its Game-changing Immunocompatible Vascular Grafts

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan |
Contact: Mireya Espinoza 
210-247-3870 mireya.espinoza[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  NAKIVO, Inc.

Visit  JobsWare.com

Visit  Triggr & Bloom







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today